Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 9/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2182453 | 0.86 | ESR1 (0.48) | ESR1ESR2CYP17A1CYP3A4CYP11B1 | |
| SCHEMBL2179318 | 0.86 | ESR1 (0.61) | ESR1ESR2PTGS1APP | |
| SCHEMBL2181362 | 0.85 | ESR1 (0.53) | ESR1ESR2PTGS1APPCYP17A1 | |
| SCHEMBL2184444 | 0.82 | ESR1 (0.55) | ESR1ESR2PTGS1APP | |
| SCHEMBL2184401 | 0.80 | ESR1 (0.56) | ESR1ESR2PTGS1APP | |
| SCHEMBL2180423 | 0.79 | ESR1 (0.45) | ESR1ESR2APPCYP11B1CYP11B2 | |
| SCHEMBL12413192 | 0.79 | ESR1 (0.43) | ESR1ESR2APP | |
| SCHEMBL12413185 | 0.77 | ESR1 (0.46) | ESR1ESR2APP | |
| SCHEMBL12413197 | 0.76 | ESR1 (0.43) | ESR1ESR2APP | |
| SCHEMBL2180745 | 0.74 | ESR1 (0.46) | ESR1ESR2APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166142-A1 | 2-SUBSTITUTED ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USES | NOVOGEN RESEARCH PTY LIMITED (AU) | 2011-07-07 | — | — | US | disclosed |
| US-20110166142-A1 | 2-SUBSTITUTED ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USES | NOVOGEN RESEARCH PTY LIMITED (AU) | 2011-07-07 | — | — | US | disclosed |
| US-20110166142-A1 | 2-SUBSTITUTED ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USES | NOVOGEN RESEARCH PTY LIMITED (AU) | 2011-07-07 | — | — | US | disclosed |
| EP-2160385-A1 | 2-SUBSTITUTED ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USES | Novogen Research Pty. Ltd. (AU) | 2010-03-10 | — | — | EP | disclosed |
| WO-2009003229-A1 | 2-SUBSTITUTED ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USES | NOVOGEN RESEARCH PTY LTD (AU) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009003229-A1 | 2-SUBSTITUTED ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USES | NOVOGEN RESEARCH PTY LTD (AU) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166142-A1 | 2-SUBSTITUTED ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USES | NFE2L2, PTGS2, PTGES2 | ESR1 90/4885ESR2 8/4885PTGS1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.